Northbank helps Australia based Phosphagenics talk to the UK markets

In January of this year Northbank initiated a financial communications programme for Phosphagenics, a Melbourne based drug delivery and nutraceutical company which floated on the London Stock Exchange AIM in July 2004. The aim of the programme was to kick start investor interest in Europe as the Company’s products and business strategy begin to take on a more global stance. Northbank has been working closely with the Company’s New York based Executive Director to develop communications with the UK market, developing good relationships with the investor community through concise realistic messaging. Since programme inception, Phosphagenics has been covered in the key drug delivery trade press, including Scrip Target and Drug Delivery Insight, and been tipped in key financial press such as Growth Company Investor and the market report of the Independent. In March of this year Phosphagenics initiated an American Depository Receipt programme with the Bank of New York to enable the trading of company stock in the US. Phosphagenics is also listed on the Australian Stock Exchange (ASX:POH)

back to news

© 2005 Northbank Communications